Announcement

Bayer Partners with Huma on Bayer Aspirin Heart Risk Assessment Tool

February 1, 2023
Announcement

Bayer Partners with Huma on Bayer Aspirin Heart Risk Assessment Tool

February 1, 2023

This is some text inside of a div block.
mins read
Speaker shot.

Speaker shot.

Speaker shot.

Huma’s predictive algorithm will power a new global online patient engagement tool* that provides an accessible solution for heart health education

NEW YORK, Feb. 1, 2023 - Huma Therapeutics Limited (“Huma”), a leading global digital health company, and Bayer, a leading global life sciences company, have partnered to develop the Bayer Aspirin Heart Risk Assessment, an online tool that quickly assesses an individual’s risk factors for developing cardiovascular disease (CVD) over the next 10 years, which can be shared with a healthcare professional as part of ongoing health management. Huma developed the algorithm using data from the UK’s Biobank which predicts long-term risk of cardiovascular disease, and the research has been validated and published in a peer-reviewed scientific journal1.

“We are tremendously excited to have the opportunity to scale our evidence-based digital innovations to advance personalised health tools like the Bayer Aspirin Risk Assessment for populations around the world.”

Dan Vahdat, CEO and Founder of Huma

Individuals will be able to engage the Heart Risk Assessment tool via https://www.bayeraspirin.com/heart-attack-and-stroke-risk-assessment/ and follow the user-friendly, 15-question prompts that will determine whether they are at higher, average, or lower risk of developing CVD by comparing their answers to those of the research population.

The tool was unveiled today in honour of Heart Month in the US and to underscore Bayer’s legacy in CVD. The aim of the tool is to reach more than 100 million people who may be at risk of CVD across the US with actionable insights to help improve their heart and overall health. Research has demonstrated an established link between an individual’s behaviours and lifestyle that have the potential to lead to adverse health outcomes, and Bayer Aspirin’s Risk Assessment aims to remind people to educate themselves about their personal risks and to have a conversation with their doctor about heart health.

“Bayer is committed to providing the public with quality healthcare solutions and is pleased to provide a cutting-edge educational resource that can effectively shape heart health conversations with anyone at risk and their physician,” said Reese Fitzpatrick, senior vice president and global marketing head, Bayer. “We are excited to partner with Huma and to leverage its pioneering digital assessment tool to help people get meaningful insights on their health in an accessible and direct way.”

Bayer is set to launch a national public awareness campaign about ongoing heart health education and risk management that will utilise this tool as a core pillar. The campaign will encourage those at elevated risk to talk to their healthcare professional about their risk profile as a proactive way to manage their health risks. Educational health information will be made available through various digital media and partner channels.

“We are tremendously excited to have the opportunity to scale our evidence-based digital innovations to advance personalised health tools like the Bayer Aspirin Risk Assessment for populations around the world.  We are honoured to have earned the trust of one of the world’s largest life sciences companies to collaborate with on this pioneering initiative,” said Dan Vahdat, CEO and Founder of Huma. “We see ourselves as part of a global movement to bring digital technology to healthcare and research and improve health outcomes for people everywhere.”

*Does not replace an assessment by a qualified healthcare professional. Always talk to your doctor or healthcare professional about your heart health.

About Huma

Huma Therapeutics is a global digital health technology company that advances digital-first care delivery and research to help people live longer, fuller lives.

Huma's award-winning modular platforms are used by more than 3,000 hospitals and clinics, with 1.8+ million active users in healthcare and 650,000+ participants across research. Huma's regulated Software as a Medical Device powers:

  • remote patient monitoring (RPM) for health systems
  • companion apps to support patients through treatment and drug therapies
  • virtual clinical trials to accelerate research

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.us or visit us on Facebook, Twitter and Instagram.

Contact (Huma):

Karen Birmingham PhD
Head of PR & Communications, Huma
karen.birmingham@huma.com

Contact (Bayer):

Nicole Hayes
Nicole.hayes@bayer

Christin Miller
Christin.miller@bayer.com

Sources:

1. European Heart Journal Digital Health. https://academic.oup.com/ehjdh/article/2/3/528/6310013

This field is required
Email must be formatted correctly
This field is required
This field is required
This field is required

Huma is committed to respecting your privacy, we’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes. You can unsubscribe at any time. Review our Privacy Policy for further information.

Keep up to date on our current work and research with the latest marketing updates from Huma, including monthly news, events and communications on products and services.

By clicking submit below, you consent to allow Huma to store and process the personal information submitted above to provide you the content requested.

One of our team members will be in touch with you shortly.
Oops! Something went wrong while submitting the form.

This field is required
This field is required
This field is required
This field is required
Thank you for your request.
You will receive an email from us shortly containing the file. Please check your inbox (and promotions tab or spam folder, if necessary) for the email.
Oops! Something went wrong while submitting the form

Email must be formatted correctly
This field is required
This field is required
This field is required
This field is required
This field is required
Country/Region*
This field is required
I'm interested in

Huma is committed to respecting your privacy, and we’ll only use your personal details to provide information you have selected you’re interested in. Review our Privacy Policy for further information.

We’d love to send you our monthly newsletter about our latest work, research and events by email. We’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes.

You’re in control. You can, of course, withdraw your consent at any time. Review our Privacy Policy for further information.

One of our team members will be in touch with you shortly.
Oops! Something went wrong while submitting the form.

Making an impact

3000+

3000+ hospitals and clinics supported across Huma platforms to secure the most sustainable impact for patients1

×2

Our platform can almost double clinical capacity and reduce readmission rates by >30%3

27m+

Huma's digital-first health platforms support a network of 27m patients1

1m+

Over 1 million devices have been shipped in support of our projects and we know what it takes to deploy at scale1

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Selected as one of 'The Most Important Healthcare Design of 2021' by Fast Company5

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Sources:

Announcement

Bayer Partners with Huma on Bayer Aspirin Heart Risk Assessment Tool

February 1, 2023
Announcement

Bayer Partners with Huma on Bayer Aspirin Heart Risk Assessment Tool

February 1, 2023

Huma joins digital pioneers to advance health equity in care and research

Chief Executive Officer and Founder, Dan Vahdat, is returning to the annual World Economic Forum’s main conference where he will join a panel discussion devoted to improving care for non-communicable disease and tackling health equity. Accompanied by Chief Financial and Strategy Officer, Ingeborg Oie, Dan is looking forward to connecting with other attendees to explore how Huma’s digital health platform can make healthcare more equitable, and advances proactive, predictive care.

Huma joins digital pioneers to advance health equity in care and research

Date:Wednesday, January 18, 2023
Time:4:15 - 5:15 p.m. CET
Location:Ice Village, Eisbahnstrasse 5, Davos, Switzerland
Dan will join the Digital Health Action Alliance panel at Davos to discuss Turning the Tide in Non-Communicable Disease Care Through Digital Health and Community Connection. Huma has a long history of advancing the care of non-communicable diseases (NCDs) such as heart disease, cancer, diabetes and lung conditions. Huma’s innovative remote patient monitoring platform enables broad patient recruitment, reduces reliance on in-person clinic visits and increases health system efficiency.
*This session is open to registered Annual Meeting 2023 participants and Affiliate badge holders.

Huma is one of the first to sign the Zero Health Gaps Pledge

Huma is one of the first signatories to the Zero Health Gaps Pledge, the World Economic Forum’s Global Health Equity Network’s (GHEN) initiative. Huma supports GHEN’s ambition to build a future without disparities in health or wellbeing outcomes. Huma’s digital platform has been built on a deep clinical knowledge of complex patient needs and how people engage with technology and we are committed to ensuring our technology promotes health equity. We are proud to work with governments, hospital groups, universities, life science and technology companies to bring greater scale and impact and help all people live longer, fuller lives.

Huma at World Economic Forum

Global Innovators and Tech Pioneers
Dec 2022: Huma selected to join 100 innovative companies on a two-year journey as part of the World Economic Forum’s initiatives, activities and events, bringing their cutting-edge insight and fresh thinking to critical global discussions.
Learn more
Working Together, Restoring Trust
May 2022: With the aim to address economic, environmental, political, and social fault-lines exacerbated by the COVID-19 pandemic, Dan Vahdat speaks at WEF annual meeting about the importance of scientific collaboration.
Learn more
Accelerating innovation and breaking new ground
October 2022: Dan joined the WEF Biotech Future Forum 2022 to discuss how start-ups are breaking new ground in biotech and changing the way we interact with the world, but also how the sector can earn trust, scale successfully and spot the brightest innovations.
Learn more
Making connections at Davos
Jan 2019: Dan attended WEF as an unofficial attendee and spoke to CNBC about the importance of meeting in-person to make connections.
Learn more

Related Articles

See more
Article
AI is in our DNA
Explore how Huma has been developing AI to revolutionise healthcare, and request a meeting with us to find out more.
Learn more
Article
“It’s really gold dust” Why Huma is a big step forward for knee surgery
Discover how Huma is providing Smith+Nephew with real world evidence for robotic knee replacement surgery.
Learn more

Related Blogs

See more
Blog
How Huma is transforming Health
Tim Broke-Smith, Huma's Vice President, Global Pharma Partnerships, considers how cutting edge technology can transform healthcare.
Learn more
Blog
Diabetes goes digital
Explore this blog featuring the Q&A session with Edith Giemula to uncover the ways in which digital tools are revolutionising diabetes research.
Learn more

Related Ebooks

See more
Ebook
Welcome to next-generation digital-first care and research
Deliver more personalised digital-first care and research with the first disease agnostic enterprise platform to achieve EU MDR Class IIb certification1.
Learn more
Ebook
What does FDA 510(k) Class II mean for Huma and our partners
Deliver more personalised digital-first care and research with our enterprise platform which now has FDA 510 (K) Class II clearance for any physician-specified condition.
Learn more

Related White Papers

See more
White Paper
Navigating the DCT transition
Learn how remote trial technology is changing the clinical trial landscape and key considerations when including DCT components in your study protocols.
Learn more
Announcement

Bayer Partners with Huma on Bayer Aspirin Heart Risk Assessment Tool

February 1, 2023
Media contact
A headshot of Karen Birmingham PhD
Karen Birmingham PhD
Head of PR & Communications
karen.birmingham@huma.com
Announcement

Bayer Partners with Huma on Bayer Aspirin Heart Risk Assessment Tool

February 1, 2023
Media contact
A headshot of Karen Birmingham PhD
Karen Birmingham PhD
Head of PR & Communications
karen.birmingham@huma.com

Huma’s predictive algorithm will power a new global online patient engagement tool* that provides an accessible solution for heart health education

NEW YORK, Feb. 1, 2023 - Huma Therapeutics Limited (“Huma”), a leading global digital health company, and Bayer, a leading global life sciences company, have partnered to develop the Bayer Aspirin Heart Risk Assessment, an online tool that quickly assesses an individual’s risk factors for developing cardiovascular disease (CVD) over the next 10 years, which can be shared with a healthcare professional as part of ongoing health management. Huma developed the algorithm using data from the UK’s Biobank which predicts long-term risk of cardiovascular disease, and the research has been validated and published in a peer-reviewed scientific journal1.

asdasd

asda

asdsads

asda

asdsad

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Download
Share this
COMPANY

About Huma

Huma began its journey in 2011, when the company was founded in London. Since then, Huma has grown to become a global healthcare company, spanning across multiple geographies and operating across four continents.

Learn more